.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,871,736

« Back to Dashboard

Details for Patent: 8,871,736

Title:Maintenance of platelet inhibition during antiplatelet therapy
Abstract: A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyridine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects diagnosed with symptoms such as stable or unstable angina, vascular ischemic events, atherosclerosis, acute coronary syndrome, as well as STEMi or N-STEMI. The described method can also be used for patients having previously received a stent, such as a bare metal stent or a drug-eluting stent, and the treatment or prevention of stent thrombosis. The method can be used prior to, during, or after an invasive procedure such as coronary artery bypass grafting, percutaneous coronary intervention, or other general surgical procedure.
Inventor(s): Chen; Lisa Ruderman (Rye, NY), Skerjanec; Simona (Pittstown, NJ), Bell; Dawn (Morristown, NJ), Steinhubl; Steven (Lexington, KY)
Assignee: The Medicines Company (Parsippany, NJ)
Filing Date:May 13, 2009
Application Number:12/990,332
Claims:1. A method of treating or inhibiting a disease or condition involving thrombosis in a subject in need of an invasive procedure who was previously treated with at least one thienopyridine, comprising administering to the subject prior to such invasive procedure an effective amount of cangrelor.

2. The method of claim 1, wherein the invasive procedure is a coronary artery bypass grafting.

3. The method of claim 1, wherein the invasive procedure is a percutaneous coronary intervention.

4. The method of claim 1, wherein the administration of cangrelor occurs within five days prior to the invasive procedure.

5. A method of treating or inhibiting a disease or condition involving thrombosis in a subject in need of an invasive procedure who was previously treated with at least one thienopyridine, comprising administering to the subject an effective amount of cangrelor to at least partially inhibit platelet activities of the subject.

6. The method of claim 5, wherein the subject has previously received a stent.

7. The method of claim 6, wherein the stent is a bare metal stent.

8. The method of claim 6, wherein the stent is a drug-eluting stent.

9. A method of at least partially inhibiting platelet activities in a subject in need thereof, comprising the steps of: administering an effective amount of at least one thienopyridine; and administering an effective amount of cangrelor after discontinuing the administration of the at least one thienopyridine.

10. The method of claim 9, wherein the at least one thienopyridine is non-reversible.

11. The method of claim 9, wherein the at least one thienopyridine is clopidogrel.

12. The method of claim 9, wherein the effective amount of cangrelor is an intravenous infusion of between 0.5 to 2.0 .mu.g/kg/min.

13. The method of claim 9, wherein platelet inhibition is greater than approximately 60%.

14. The method of claim 9, wherein administration of cangrelor occurs within five days prior to an invasive procedure to be performed on the subject.

15. The method of claim 9, wherein administration of cangrelor occurs during an invasive procedure being performed on the subject.

16. The method of claim 9, wherein administration of cangrelor occurs after an invasive procedure performed on the subject.

17. A method of at least partially inhibiting platelet activities in a subject in need thereof previously treated with at least one thienopyridine, comprising administering to the subject an effective amount of cangrelor.

18. The method of claim 17, wherein the at least one thienopyridine is clopidogrel.

19. The method of claim 17, wherein administration of cangrelor begins at least five days prior to an invasive procedure.

20. The method of claim 19, wherein administration of cangrelor is discontinued between 1 and 24 hours prior to the invasive procedure.

21. A method of inhibiting a platelet activity in a subject in need thereof, comprising: (a) administering a therapeutically effective amount of at least one thienopyridine to the subject; (b) discontinuing administration of the at least one thienopyridine to the subject; and (c) administering a therapeutically effective amount of cangrelor to the subject, inhibiting platelet activity in the subject.

22. The method of claim 21, wherein the inhibitory activity of the at least one thienopyridine is non-reversible.

23. The method of claim 21, wherein the at least one thienopyridine is clopidogrel.

24. The method of claim 21, wherein the therapeutically effective amount of cangrelor is an intravenous infusion of between about 0.5 and about 2.0 .mu.g/kg/min.

25. The method of claim 21, wherein the inhibition of platelet activity is an inhibition of greater than approximately 60% of platelet aggregation.

26. The method of claim 21, wherein the platelet activity is platelet aggregation.

27. The method of claim 21, wherein the discontinuation of administration of the at least one thienopyridine to the subject occurs at least five days prior to an invasive procedure to be performed on the subject.

28. The method of claim 27, wherein administration of cangrelor begins prior to the invasive procedure.

29. The method of claim 27, wherein administration of cangrelor begins during the invasive procedure.

30. The method of claim 27, wherein administration of cangrelor begins after the invasive procedure.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc